{"id":"pg201-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL635","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, PG201 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of PG201's interaction with SGLT2 are not well-documented.","oneSentence":"PG201 tablet is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:22.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01122485","phase":"PHASE2","title":"Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis","status":"WITHDRAWN","sponsor":"Helixmith Co., Ltd.","startDate":"2006-12","conditions":"Osteoarthritis of the Knee","enrollment":""},{"nctId":"NCT01576419","phase":"PHASE3","title":"Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients","status":"COMPLETED","sponsor":"PMG Pharm Co., Ltd","startDate":"2010-01","conditions":"Osteoarthritis of the Knee","enrollment":309}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["botanical drug"],"phase":"phase_3","status":"active","brandName":"PG201 tablet","genericName":"PG201 tablet","companyName":"PMG Pharm Co., Ltd","companyId":"pmg-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PG201 tablet is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}